<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Various strategies have been tested to identify serum biomarkers in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, the entire of proteins released by cultured <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells into the media, the so-called secretome, has been suggested as a promising source for biomarker discovery </plain></SENT>
<SENT sid="2" pm="."><plain>Ectodomains of membrane proteins cleaved from the cell surface represent a surprisingly abundant and apparently stable subset of this subproteome </plain></SENT>
<SENT sid="3" pm="."><plain>Aiming for the detection of serum biomarkers for patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), we have previously detected significant amounts of the soluble form of E-cadherin in the secretomes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report a comprehensive analysis of sE-cadherin levels in sera from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath>, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> and <z:e sem="disease" ids="C0032580" disease_type="Neoplastic Process" abbrv="">familial adenomatous polyposis</z:e> (FAP) </plain></SENT>
<SENT sid="5" pm="."><plain>Whereas mean sE-cadherin levels in patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (mean: 4.7 μg/ml, SD: 1.5 μg/ml), with <z:mpath ids='MPATH_270'>adenomas</z:mpath> (mean: 4.6 μg/ml, SD: 3.0 μg/ml) and early stage <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (mean: 4.9 μg/ml, SD: 4.7 μg/ml) do not significantly differ from healthy controls (mean: 4.8 μg/ml, SD: 1.9 μg/ml), patients with Stage III and Stage IV <z:mp ids='MP_0002038'>carcinomas</z:mp> display a significant increase (mean: 6.1 μg/ml, SD: 2.6 μg/ml) </plain></SENT>
<SENT sid="6" pm="."><plain>In individual patients with late-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, sE-cadherin serum levels directly reflect their disease status over time </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest a potential application of sE-cadherin as an alternative diagnostic biomarker for monitoring disease particularly in patients with carcinoembryonic antigen negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In patients with FAP, on the other hand, we also detected a significant increase of serum sE-cadherin levels (mean: 5.8 μg/ml, SD: 2.8 μg/ml), but this was regardless of their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load and colectomy status </plain></SENT>
</text></document>